Earnings Feed
Start Free
Contineum Therapeutics, Inc.·4

Jul 2, 5:47 PM ET

Lorrain Daniel S. 4

4 · Contineum Therapeutics, Inc. · Filed Jul 2, 2026

Research Summary

AI-generated summary of this filing

Updated

Contineum (CTNM) CSO Daniel S. Lorrain Sells Shares After Exercising Options

What Happened
Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), exercised stock options and sold common shares in transactions reported on a Form 4. He exercised 33,009 shares (28,826 on 2026-06-30 and 4,183 on 2026-07-01) at $1.01 per share (exercise cost ≈ $33,339). He sold a total of 37,179 shares in open-market transactions (28,826 on 2026-06-30 at a weighted avg $16.04; 5,852 on 2026-07-01 at $15.67; and 2,501 on 2026-07-01 at $16.24), producing gross sale proceeds of approximately $594,578. The exercised shares were disposed in the market (i.e., shares were sold after exercise).

Key Details

  • Transaction dates: 2026-06-30 and 2026-07-01; Form 4 filed 2026-07-02 (within the normal reporting window).
  • Exercise details: 33,009 shares exercised at $1.01 each (total cost ≈ $33,339). Footnote F6: options are fully vested and exercisable.
  • Sales details and price ranges:
    • 28,826 shares sold 6/30 — weighted avg $16.04 (range $16.00–$16.35) — proceeds $462,288 (F2).
    • 5,852 shares sold 7/01 — weighted avg $15.67 (range $15.15–$16.14) — proceeds $91,682 (F3).
    • 2,501 shares sold 7/01 — weighted avg $16.24 (range $16.16–$16.40) — proceeds $40,608 (F4).
  • Gross sale proceeds ≈ $594,578; exercise cost ≈ $33,339 (net before fees/taxes ≈ $561,239).
  • Plan/authorization: Transactions effected pursuant to a 10b5-1 trading plan adopted 9/23/2025 (F1).
  • Other notes: Filing footnotes mention a spouse ESPP purchase (F5). The filing shows derivative conversion entries at $0.00 reflecting the option exercise/conversion into shares.

Context

  • This is effectively a cashless exercise pattern: options were exercised and resulting shares were sold in the open market shortly thereafter. That is common for executives exercising vested options to cover exercise costs and taxes; it is a sale rather than a new ownership stake.
  • No indication in the provided excerpt of late filing. The Form 4 covering 6/30 transactions was filed on 7/02/2026, which is within the typical two-business-day Form 4 reporting window.
  • Shares owned after the transactions are not specified in the excerpt provided.

Insider Transaction Report

Form 4
Period: 2026-06-30
Contineum Therapeutics, Inc.CTNM
Lorrain Daniel S.
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Class A Common Stock

    [F1]
    2026-06-30$1.01/sh+28,826$29,114→ 168,198 total
  • Sale

    Class A Common Stock

    [F1][F2]
    2026-06-30$16.04/sh−28,826$462,288→ 139,372 total
  • Exercise/Conversion

    Class A Common Stock

    [F1]
    2026-07-01$1.01/sh+4,183$4,225→ 143,555 total
  • Sale

    Class A Common Stock

    [F1][F3]
    2026-07-01$15.67/sh−5,852$91,682→ 137,703 total
  • Sale

    Class A Common Stock

    [F1][F4]
    2026-07-01$16.24/sh−2,501$40,608→ 135,202 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F6]
    2026-06-30−28,826→ 38,480 total
    Exercise: $1.01Exp: 2030-02-24→ Class A Common Stock (28,826 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F6]
    2026-07-01−4,183→ 34,297 total
    Exercise: $1.01Exp: 2030-02-24→ Class A Common Stock (4,183 underlying)
Holdings

  • Class A Common Stock

    [F5]
    (indirect: By Spouse)
    10,110
Footnotes (6)
  • [F1]These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.35, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.40, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  • [F5]Includes 6,537 shares of the Issuer's Class A Common Stock acquired by the Reporting Person's spouse in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
  • [F6]The stock options are fully vested and exercisable.
Signature
/s/ Peter Slover, Attorney-in-Fact|2026-07-02

Documents

1 file
  • 4
    wk-form4_1783028831.xmlPrimary

    FORM 4